Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Anti-inflammatory Effect of the Water-Soluble Portion of Porcine Placental Extract in Lipopolysaccharide-Stimulated RAW264.7 Murine Macrophage Cells.

Tebakari M, Daigo Y, Ishikawa H, Nakamura M, Kawashima J, Takano F.

Biol Pharm Bull. 2018;41(8):1251-1256. doi: 10.1248/bpb.b18-00199.

2.

High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers.

Baghdadi M, Endo H, Takano A, Ishikawa K, Kameda Y, Wada H, Miyagi Y, Yokose T, Ito H, Nakayama H, Daigo Y, Suzuki N, Seino KI.

Sci Rep. 2018 Jan 11;8(1):418. doi: 10.1038/s41598-017-18796-8.

3.

Maternal undernutrition during early pregnancy inhibits postnatal growth of the tibia in the female offspring of rats by alteration of chondrogenesis.

Kimura T, Hino K, Kono T, Takano A, Nitta N, Ushio N, Hino S, Takase R, Kudo M, Daigo Y, Morita W, Nakao M, Nakatsukasa M, Tamagawa T, Rafiq AM, Matsumoto A, Otani H, Udagawa J.

Gen Comp Endocrinol. 2018 May 1;260:58-66. doi: 10.1016/j.ygcen.2017.12.008. Epub 2017 Dec 23.

PMID:
29277418
4.

Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer.

Daigo K, Takano A, Thang PM, Yoshitake Y, Shinohara M, Tohnai I, Murakami Y, Maegawa J, Daigo Y.

Int J Oncol. 2018 Jan;52(1):155-165. doi: 10.3892/ijo.2017.4181. Epub 2017 Oct 31.

5.

The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.

Igarashi T, Teramoto K, Ishida M, Hanaoka J, Daigo Y.

Oncol Rep. 2017 Oct;38(4):2189-2196. doi: 10.3892/or.2017.5876. Epub 2017 Aug 3.

PMID:
28791392
6.

Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine.

Mai T, Takano A, Suzuki H, Hirose T, Mori T, Teramoto K, Kiyotani K, Nakamura Y, Daigo Y.

Oncol Lett. 2017 Jul;14(1):283-292. doi: 10.3892/ol.2017.6125. Epub 2017 May 5.

7.

Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer.

Teramoto K, Ozaki Y, Hanaoka J, Sawai S, Tezuka N, Fujino S, Daigo Y, Kontani K.

Ther Adv Med Oncol. 2017 Mar;9(3):147-157. doi: 10.1177/1758834016678375. Epub 2016 Nov 24.

8.

Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations.

Seow WJ, Matsuo K, Hsiung CA, Shiraishi K, Song M, Kim HN, Wong MP, Hong YC, Hosgood HD 3rd, Wang Z, Chang IS, Wang JC, Chatterjee N, Tucker M, Wei H, Mitsudomi T, Zheng W, Kim JH, Zhou B, Caporaso NE, Albanes D, Shin MH, Chung LP, An SJ, Wang P, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Bassig BA, Chang J, Ho JC, Ji BT, Kubo M, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Nokihara H, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Shi J, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Wong JY, Matsuda F, Su J, Kim YH, Oh IJ, Song F, Lee VH, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Yang PC, Lin HC, Xiang YB, Seow A, Park JY, Kweon SS, Chen CJ, Li H, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Wang WC, Chung CC, Lawrence C, Burdett L, Yeager M, Jacobs KB, Hutchinson A, Berndt SI, He X, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Hu L, Chen CH, Yang TY, Xu J, Guan P, Tan W, Wang CL, Sihoe AD, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chan JK, Chu M, Li YJ, Li J, Chen H, Yu CJ, Jin L, Lo YL, Chen YH, Fraumeni JF Jr, Liu J, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Wu G, Chien LH, Chen HL, Su YC, Tsai FY, Chen YS, Yu J, Stevens VL, Laird-Offringa IA, Marconett CN, Lin D, Chen K, Wu YL, Landi MT, Shen H, Rothman N, Kohno T, Chanock SJ, Lan Q.

Hum Mol Genet. 2017 Jan 15;26(2):454-465. doi: 10.1093/hmg/ddw414.

9.

RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.

Sumimoto H, Takano A, Teramoto K, Daigo Y.

PLoS One. 2016 Nov 15;11(11):e0166626. doi: 10.1371/journal.pone.0166626. eCollection 2016.

10.

Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors.

Igarashi T, Teramoto K, Ishida M, Hanaoka J, Daigo Y.

ESMO Open. 2016 Aug 26;1(4):e000083. eCollection 2016.

11.

Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells.

Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino KI.

Cancer Res. 2016 Oct 15;76(20):6030-6042. Epub 2016 Aug 22.

12.

Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.

Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, Kunitoh H, Matsumoto S, Takano A, Shimizu K, Goto A, Tsuta K, Watanabe S, Ohe Y, Watanabe Y, Goto Y, Nokihara H, Furuta K, Yoshida A, Goto K, Hishida T, Tsuboi M, Tsuchihara K, Miyagi Y, Nakayama H, Yokose T, Tanaka K, Nagashima T, Ohtaki Y, Maeda D, Imai K, Minamiya Y, Sakamoto H, Saito A, Shimada Y, Sunami K, Saito M, Inazawa J, Nakamura Y, Yoshida T, Yokota J, Matsuda F, Matsuo K, Daigo Y, Kubo M, Kohno T.

Nat Commun. 2016 Aug 9;7:12451. doi: 10.1038/ncomms12451.

13.

Cell division cycle associated 1 as a novel prognostic biomarker and therapeutic target for oral cancer.

Thang PM, Takano A, Yoshitake Y, Shinohara M, Murakami Y, Daigo Y.

Int J Oncol. 2016 Oct;49(4):1385-93. doi: 10.3892/ijo.2016.3649. Epub 2016 Aug 5.

PMID:
27499128
14.

Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.

Nishii T, Yokose T, Miyagi Y, Daigo Y, Isaka T, Furumoto H, Ito H, Murakami S, Kondo T, Saito H, Oshita F, Yamada K, Matsukuma S, Nakayama H, Masuda M.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e204-e211. doi: 10.1111/ajco.12512. Epub 2016 Jun 28.

PMID:
27349355
15.

Investigation of Optimal Time for Starting Betamethasone Using Fatigue Scores and Prognostic Nutritional Index in Terminally Ill Patients With Cancer-Related Fatigue.

Koyama N, Matsumura C, Morii H, Hasegawa C, Hira D, Daigo Y, Terada T, Yano Y.

Am J Hosp Palliat Care. 2017 Jun;34(5):449-455. doi: 10.1177/1049909116632487. Epub 2016 Feb 16.

PMID:
26888884
16.

Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women.

Wang Z, Seow WJ, Shiraishi K, Hsiung CA, Matsuo K, Liu J, Chen K, Yamji T, Yang Y, Chang IS, Wu C, Hong YC, Burdett L, Wyatt K, Chung CC, Li SA, Yeager M, Hutchinson A, Hu W, Caporaso N, Landi MT, Chatterjee N, Song M, Fraumeni JF Jr, Kohno T, Yokota J, Kunitoh H, Ashikawa K, Momozawa Y, Daigo Y, Mitsudomi T, Yatabe Y, Hida T, Hu Z, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Yin Z, Li X, Ren Y, Guan P, Chang J, Tan W, Chen CJ, Chang GC, Tsai YH, Su WC, Chen KY, Huang MS, Chen YM, Zheng H, Li H, Cui P, Guo H, Xu P, Liu L, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Park JY, Kim YH, Sung JS, Park KH, Kim YT, Jung YJ, Kang CH, Park IK, Kim HN, Jeon HS, Choi JE, Choi YY, Kim JH, Oh IJ, Kim YC, Sung SW, Kim JS, Yoon HI, Kweon SS, Shin MH, Seow A, Chen Y, Lim WY, Liu J, Wong MP, Lee VH, Bassig BA, Tucker M, Berndt SI, Chow WH, Ji BT, Wang J, Xu J, Sihoe AD, Ho JC, Chan JK, Wang JC, Lu D, Zhao X, Zhao Z, Wu J, Chen H, Jin L, Wei F, Wu G, An SJ, Zhang XC, Su J, Wu YL, Gao YT, Xiang YB, He X, Li J, Zheng W, Shu XO, Cai Q, Klein R, Pao W, Lawrence C, Hosgood HD 3rd, Hsiao CF, Chien LH, Chen YH, Chen CH, Wang WC, Chen CY, Wang CL, Yu CJ, Chen HL, Su YC, Tsai FY, Chen YS, Li YJ, Yang TY, Lin CC, Yang PC, Wu T, Lin D, Zhou B, Yu J, Shen H, Kubo M, Chanock SJ, Rothman N, Lan Q.

Hum Mol Genet. 2016 Feb 1;25(3):620-9. doi: 10.1093/hmg/ddv494. Epub 2016 Jan 4.

17.

Regulation of iron homeostasis by the p53-ISCU pathway.

Funauchi Y, Tanikawa C, Yi Lo PH, Mori J, Daigo Y, Takano A, Miyagi Y, Okawa A, Nakamura Y, Matsuda K.

Sci Rep. 2015 Nov 12;5:16497. doi: 10.1038/srep16497.

18.

Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS).

Fang H, Yamaguchi R, Liu X, Daigo Y, Yew PY, Tanikawa C, Matsuda K, Imoto S, Miyano S, Nakamura Y.

Oncoimmunology. 2015 Jan 7;3(12):e968467. eCollection 2014 Dec.

19.

[Assessment of anticancer drug-induced adverse event].

Takano A, Daigo Y.

Nihon Rinsho. 2015 Feb;73 Suppl 2:75-8. Japanese. No abstract available.

PMID:
25831727
20.

A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.

Kusakabe K, Ide N, Daigo Y, Itoh T, Yamamoto T, Kojima E, Mitsuoka Y, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Yoshizawa H, Murai H, Nakamura Y.

Bioorg Med Chem. 2015 May 1;23(9):2247-60. doi: 10.1016/j.bmc.2015.02.042. Epub 2015 Mar 4.

PMID:
25801152
21.

Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.

Kusakabe K, Ide N, Daigo Y, Itoh T, Yamamoto T, Hashizume H, Nozu K, Yoshida H, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Baba Y, Nakamura Y.

J Med Chem. 2015 Feb 26;58(4):1760-75. doi: 10.1021/jm501599u. Epub 2015 Feb 10.

PMID:
25625617
22.

Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.

Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, Daigo Y, Ogasawara K.

Cancer Sci. 2015 Feb;106(2):134-42. doi: 10.1111/cas.12584. Epub 2015 Jan 16.

23.

Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease.

Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y.

Oncoimmunology. 2014 Mar 27;3:e28100. eCollection 2014.

24.

Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.

Nishii T, Yokose T, Miyagi Y, Daigo Y, Ito H, Isaka T, Imai K, Murakami S, Kondo T, Saito H, Oshita F, Yamada K, Matsukuma S, Tsuboi M, Nakayama H, Masuda M.

BMC Cancer. 2014 Aug 25;14:610. doi: 10.1186/1471-2407-14-610.

25.

Identification of a nuclear protein, LRRC42, involved in lung carcinogenesis.

Fujitomo T, Daigo Y, Matsuda K, Ueda K, Nakamura Y.

Int J Oncol. 2014 Jul;45(1):147-56. doi: 10.3892/ijo.2014.2418. Epub 2014 May 6.

PMID:
24806090
26.

Cell division cycle-associated protein 1 overexpression is essential for the malignant potential of colorectal cancers.

Kobayashi Y, Takano A, Miyagi Y, Tsuchiya E, Sonoda H, Shimizu T, Okabe H, Tani T, Fujiyama Y, Daigo Y.

Int J Oncol. 2014 Jan;44(1):69-77. doi: 10.3892/ijo.2013.2177. Epub 2013 Nov 15.

PMID:
24247253
27.

RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer.

Oshita H, Nishino R, Takano A, Fujitomo T, Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.

Mol Cancer Res. 2013 Aug;11(8):937-51. doi: 10.1158/1541-7786.MCR-12-0685-T. Epub 2013 May 16.

28.

A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses.

Daigo Y, Takano A, Teramoto K, Chung S, Nakamura Y.

Clin Pharmacol Ther. 2013 Aug;94(2):218-23. doi: 10.1038/clpt.2013.90. Epub 2013 May 8. Review.

PMID:
23657161
29.

Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).

Kusakabe K, Ide N, Daigo Y, Tachibana Y, Itoh T, Yamamoto T, Hashizume H, Hato Y, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Yasuo K, Maeda M, Higaki M, Ueda K, Yoshizawa H, Baba Y, Shiota T, Murai H, Nakamura Y.

J Med Chem. 2013 Jun 13;56(11):4343-56. doi: 10.1021/jm4000215. Epub 2013 May 24.

PMID:
23634759
30.

Cytocompatibility and mechanical properties of novel porous 316 L stainless steel.

Kato K, Yamamoto A, Ochiai S, Wada M, Daigo Y, Kita K, Omori K.

Mater Sci Eng C Mater Biol Appl. 2013 Jul 1;33(5):2736-43. doi: 10.1016/j.msec.2013.02.038. Epub 2013 Feb 28.

PMID:
23623090
31.

Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.

Kogure M, Takawa M, Cho HS, Toyokawa G, Hayashi K, Tsunoda T, Kobayashi T, Daigo Y, Sugiyama M, Atomi Y, Nakamura Y, Hamamoto R.

Cancer Lett. 2013 Aug 9;336(1):76-84. doi: 10.1016/j.canlet.2013.04.009. Epub 2013 Apr 18.

PMID:
23603248
32.

Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions.

Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, Kamihagi K, Koyama N, Yamada S, Daigo Y, Nakamura Y, Taniguchi N, Miyoshi E.

Clin Chim Acta. 2013 Feb 18;417:48-53. doi: 10.1016/j.cca.2012.12.014. Epub 2012 Dec 21.

PMID:
23262369
33.

[Cancer peptide vaccine therapy based on human genomics approach].

Daigo Y.

Nihon Rinsho. 2012 Dec;70(12):2114-7. Review. Japanese.

PMID:
23259382
34.

Novel multilayer Ti foam with cortical bone strength and cytocompatibility.

Kato K, Ochiai S, Yamamoto A, Daigo Y, Honma K, Matano S, Omori K.

Acta Biomater. 2013 Mar;9(3):5802-9. doi: 10.1016/j.actbio.2012.11.018. Epub 2012 Nov 29.

PMID:
23201016
35.

Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B.

Cho HS, Shimazu T, Toyokawa G, Daigo Y, Maehara Y, Hayami S, Ito A, Masuda K, Ikawa N, Field HI, Tsuchiya E, Ohnuma S, Ponder BA, Yoshida M, Nakamura Y, Hamamoto R.

Nat Commun. 2012;3:1072. doi: 10.1038/ncomms2074.

36.

Identification of a novel oncogene, MMS22L, involved in lung and esophageal carcinogenesis.

Nguyen MH, Ueda K, Nakamura Y, Daigo Y.

Int J Oncol. 2012 Oct;41(4):1285-96. doi: 10.3892/ijo.2012.1589. Epub 2012 Aug 10.

PMID:
22895565
37.

A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population.

Shiraishi K, Kunitoh H, Daigo Y, Takahashi A, Goto K, Sakamoto H, Ohnami S, Shimada Y, Ashikawa K, Saito A, Watanabe S, Tsuta K, Kamatani N, Yoshida T, Nakamura Y, Yokota J, Kubo M, Kohno T.

Nat Genet. 2012 Jul 15;44(8):900-3. doi: 10.1038/ng.2353.

PMID:
22797724
38.

Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.

Kusakabe K, Ide N, Daigo Y, Itoh T, Higashino K, Okano Y, Tadano G, Tachibana Y, Sato Y, Inoue M, Wada T, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Tagashira S, Kido Y, Sakamoto S, Yasuo K, Maeda M, Yamamoto T, Higaki M, Endoh T, Ueda K, Shiota T, Murai H, Nakamura Y.

ACS Med Chem Lett. 2012 Jun 6;3(7):560-4. doi: 10.1021/ml3000879. eCollection 2012 Jul 12.

39.

Critical function for nuclear envelope protein TMEM209 in human pulmonary carcinogenesis.

Fujitomo T, Daigo Y, Matsuda K, Ueda K, Nakamura Y.

Cancer Res. 2012 Aug 15;72(16):4110-8. doi: 10.1158/0008-5472.CAN-12-0159. Epub 2012 Jun 19.

40.

Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients.

Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M.

J Surg Oncol. 2012 Sep 15;106(4):423-30. doi: 10.1002/jso.23109. Epub 2012 Apr 4.

PMID:
22488197
41.

Regulation of histone modification and chromatin structure by the p53-PADI4 pathway.

Tanikawa C, Espinosa M, Suzuki A, Masuda K, Yamamoto K, Tsuchiya E, Ueda K, Daigo Y, Nakamura Y, Matsuda K.

Nat Commun. 2012 Feb 14;3:676. doi: 10.1038/ncomms1676. Erratum in: Nat Commun. 2013;4:2638.

PMID:
22334079
42.

Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis.

Koinuma J, Akiyama H, Fujita M, Hosokawa M, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y.

Cancer Sci. 2012 Mar;103(3):577-86. doi: 10.1111/j.1349-7006.2011.02167.x. Epub 2012 Jan 9.

43.

Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.

Toyokawa G, Cho HS, Masuda K, Yamane Y, Yoshimatsu M, Hayami S, Takawa M, Iwai Y, Daigo Y, Tsuchiya E, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, Nakamura Y, Hamamoto R.

Neoplasia. 2011 Oct;13(10):887-98.

44.

The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene.

Cho HS, Toyokawa G, Daigo Y, Hayami S, Masuda K, Ikawa N, Yamane Y, Maejima K, Tsunoda T, Field HI, Kelly JD, Neal DE, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R.

Int J Cancer. 2012 Aug 1;131(3):E179-89. doi: 10.1002/ijc.26501. Epub 2011 Dec 21.

45.

Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.

Masuda K, Takano A, Oshita H, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.

Clin Cancer Res. 2011 Dec 15;17(24):7712-22. doi: 10.1158/1078-0432.CCR-11-0619. Epub 2011 Oct 20.

46.

Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer.

Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.

Clin Cancer Res. 2011 Oct 1;17(19):6272-86. doi: 10.1158/1078-0432.CCR-11-0060. Epub 2011 Aug 17.

47.

Characterization of a cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer.

Aragaki M, Takahashi K, Akiyama H, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y.

Clin Cancer Res. 2011 Sep 15;17(18):5889-900. doi: 10.1158/1078-0432.CCR-11-0240. Epub 2011 Aug 3.

48.

Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients.

Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M.

Lung Cancer. 2012 Jan;75(1):110-8. doi: 10.1016/j.lungcan.2011.05.024.

PMID:
21689861
49.

Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer.

Toyokawa G, Masuda K, Daigo Y, Cho HS, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Chino M, Field HI, Neal DE, Tsuchiya E, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R.

Mol Cancer. 2011 May 28;10:65. doi: 10.1186/1476-4598-10-65.

50.

Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.

Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, Field HI, Kobayashi T, Akasu T, Sugiyama M, Tsuchiya E, Atomi Y, Ponder BA, Nakamura Y, Hamamoto R.

Cancer Sci. 2011 Jul;102(7):1298-305. doi: 10.1111/j.1349-7006.2011.01958.x. Epub 2011 May 26.

Supplemental Content

Support Center